How the fund has performed
Where the fund invests
Basic facts
Date of launch: 16 Feb, 1993
Category: Equity
Type: Large & Midcap
AUM (As on 30 Sep, 2021): Rs 1,196 cr
Benchmark: NIFTY Large Midcap 250 Total Return Index
What it costs
NAV (As on 19 Oct, 2021)
Growth option: Rs 103.47
IDCW: Rs 50.40
Minimum Investment: Rs 5,000
Minimum SIP amount: Rs 500
Expense ratio (As on 31 August, 2021) (%): 2.53
Exit load: 1% for redemption within 364 days
Fund Manager: V. Srivatsa
Tenure: 4 years, 4 months
Top 5 sectors in portfolio (%)
Top 5 stocks in portfolio (%)
Recent portfolio changes
New Entrants: Dr. Reddy’s Laboratories, G R Infraprojects, HPCL, Oracle Financial Services Software, Aditya Birla Sun Life AMC
Complete Exits: Cadila Healthcare, LIC Housing Finance, Bharat Petroleum Corporation, DCM Shriram
How risky is it?
Source: Value Research
Should you buy?
Earlier run as a large-cap oriented offering (UTI Top 100), this fund was repositioned in the large-and-mid cap category a few years ago. While its midcap presence is now elevated, it retains its large-cap tilt for the stability and liquidity it brings. It also chooses to have modest exposure to small-caps given limited opportunities in mid-cap basket. The fund manager follows a relative value approach, avoiding paying for expensive growth names. It also invests partly in cyclicals and turnaround or restructuring stories. The fund performance suffered during 2018-20 but has picked up smartly over the past year. Having a patchy long-term track record, the fund needs to show sustained improvement in return profile.
